CNCR SHORT IDEALook for confirmation. On strong uptrend = lookout for stopout.
At double major support. Look to either break through and rocket higher or take a hard fall.
Key stats
About Range Cancer Therapeutics ETF
Expense ratio
0.79%
Home page
Inception date
Oct 13, 2015
CNCR takes an approach to niche coverage within the healthcare sector. It provides equal-weighted exposure to companies that generate their revenue from oncology products or are in constant development and production of cancer therapeutic medicine. Cancer Therapeutics is a term used to refer to the wide range of treatments and interventions used to treat various kinds of cancer. Equal weighting of the securities draws attention to smaller companies with room to grow. This fund provides a unique option for investors placing a highly specialized bet on this space. Prior to June 20, 2023, the fund tracked the Loncar Cancer Immunotherapy Index and traded under the name Loncar Cancer Immunotherapy ETF. Effective October 20, 2023, the Loncar China BioPharma ETF that traded under the symbol CHNA merged into CNCR, acquiring its assets and expanding the funds exposure to China. Before June 3, 2024, the fund's index name swapped Cancer for Oncology, keeping the strategy unchanged.
Classification
What's in the fund
Exposure type
Health Technology
Stock breakdown by region
CNCR breakouts heading to All time HighsLooks like CNCR is heading to ATH of 31.70 after moving sideways for months.
Let me know your thoughts
Top Biotech ETFThis is CNCR Loncar Cancer Immunotherapy ETF, it is trading +25% year to date, some of its 30 holdings are ATRA, IOVA, NKTR, JNCE, BGNE, ACEN, 64% in Micro Cap, last price $30.60, expense ratio 0.79%. We are bullish on it and you could too.
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.